The utilization of predicted splice donor and acceptor sites in generating equine infectious anemia virus (EIAV) transcripts in fetal donkey dermal cells (FDD) was examined. A single splice donor site identified immediately upstream of the gag coding region joins the viral leader sequence to all downstream exons of spliced EIAV transcripts. The predominant 3.5-kb transcript synthesized in EIAV-infected FDD cells appears to be generated by a single splicing event which links the leader sequence to the first of two functional splice acceptor sites near the 5' end of the Si open reading frame (ORF). The translation products encoded by the 3.5-kb transcript were examined by producing in vitro transcripts from a cDNA corresponding to this RNA followed by in vitro translation in wheat germ extracts. These transcripts directed the synthesis of three proteins: the virus trans-activator protein (EIAV Tat) encoded by ORF S1, a protein of unknown function encoded by ORF S2, and the virus envelope glycoprotein. When transfected into FDD cells, this cDNA also directed expression of EIAV Tat. Amino-terminal sequence analysis of the in vitro-synthesized Si protein supports the suggestion that translation of EIAV Tat is initiated at a CUG codon within the virus leader region. Both in vitro-synthesized S2 protein and synthetic peptides corresponding to S2 are shown to react positively with sera obtained from EIAV-infected horses, providing the first direct evidence of expression of this protein in infected animals.
Equine infectious anemia virus (EIAV) is a member of the lentivirus subfamily of retroviruses, a group that includes the ungulate (visna-maedi, caprine arthritis-encephalitis, and bovine immunodeficiency-like viruses) and the primate (human immunodeficiency virus types 1 and 2 [HIV-1 and HIV-2] and simian immunodeficiency virus) retroviruses (18) . The genetic organization of EIAV is relatively simple compared with that of other lentiviruses (6) in that the gene contains only three short open reading frames (ORFs), Si, S2, and S3, in addition to the gag, pol, and env genes common to all replication-competent retroviruses. ORF Si is located within the pol-env intergenic region, while ORF S2 begins between ORF S1 and env and overlaps the amino terminus of the env gene in a different reading frame. ORF S3 is positioned near the 3' end of the genome and is encoded within an alternate reading frame overlapping the gp45-coding sequence of the env gene. The Si gene product, which shares both structural and functional homology with the Tat protein of HIV-1, has been identified as the EIAV trans-activator protein (8, 20, 30) . Although ORF S1 contains no AUG codon, it has been suggested that translation of EIAV Tat may begin at a CUG codon within the viral leader sequence, which is joined in-frame with Si as a result of an RNA splicing event (8, 30) . On the basis of sequence homology with HIV-1 Rev and nonsense mutations within S3, which seem to impart a Rev-defective phenotype to EIAV-infected canine cells (30) , ORF S3 is believed to encode the EIAV Rev protein. The predicted protein en-coded by ORF S2 bears no significant homology to any of the lentiviral ancillary proteins described to date and has yet to be assigned a function. Thus far, no transcript or protein product that corresponds to expression of ORF S2 has been identified.
EIAV gene expression has been primarily studied in canine and feline fibroblast cultures which are permissive for persistent EIAV infections. Analyses of RNA transcription patterns in such cells yielded variable observations in the temporal appearance and abundance of EIAV-specific transcripts (8, 21, 30) . The simplest and most consistent transcription patterns were observed in EIAV-infected primary horse macrophage cultures and equine fibroblasts (fetal equine kidney [FEK] and fetal donkey dermal [FDD] cells), which predominantly synthesized transcripts corresponding to the 8.2-kb genomic RNA and the presumably singly spliced 3.5-kb envelope message (25, 30) . Small multiply spliced transcripts of 1 to 2 kb were mainly undetectable in EIAV-infected equine cells, a surprising observation, since viral trans-activation factors are expressed in EIAV-infected equine fibroblasts (25) . In the present work, we have systematically examined the splicing patterns of EIAV in FDD cells by using cDNA cloning, Northern (RNA) blot hybridization, and nuclease S1 protection assays.
Previous studies in our laboratory showed that EIAV infection of cultured FDD cells resulted in a cytopathic infection, whereas FEK cells became persistently infected in vitro (25) . Interestingly, in cytopathically infected FDD cells, the proportion of 3.5-kb mRNA to full-length 8.2-kb transcript was substantially greater than in persistently infected FEK cells, which synthesized the two RNAs in approximately equal abundance at all stages of infection.
Examination of the properties of the predominant 3.5-kb EIAV transcript of FDD cells might provide some insight into the mechanisms of cytopathicity observed in this cell type. To address this question as part of the study described in this report, in vitro transcripts were generated from a cDNA derived from the 3.5-kb RNA and used to prime translation in wheat germ extracts. These transcripts were found to produce the Si, S2, and envelope proteins of EIAV as confirmed by radioimmunoprecipitation assays and amino-terminal sequence analyses of Si and S2. Sequence analysis of the Si EIAV Tat protein was consistent with the suggestion of translational initiation at a CUG codon within the leader region. The S2 protein was specifically immunoprecipitated by sera from EIAV-infected horses, demonstrating its production during EIAV infection of host animals. The 3.5-kb RNA-derived cDNA was also tested for encoding trans-activation factors in cultured FDD cells by cotransfection of a simian virus 40 (SV40) replacement vector containing the cDNA with a long terminal repeat (LTR)-driven reporter plasmid. The results of these studies are presented in this report.
MATERIALS AND METHODS Virus strains and cell cultures. Primary cultures of FDD cells were prepared and maintained as previously described (24, 25) . An FDD-adapted stock of prototype EIAV was utilized in these studies. This stock was generated by propagation of the Wyoming cell-adapted strain of EIAV (15) in primary cultures of FEK cells to produce prototype virus followed by serial passage in FDD cells. Confluent monolayers of FDD cells were infected with FDD-adapted virus at a multiplicity of infection of 1. Cells were harvested for RNA isolation as previously described (25) .
Isolation and purification of RNA. Total cellular RNA was isolated from EIAV-infected or uninfected FDD cells by a modified guanidinium thiocyanate extraction method (4, 16) as previously described (25) . Poly(A)+ RNA was purified by two cycles of oligo(dT)-cellulose chromatography of total cellular RNA (16) (27) .
Northern blot analysis. Poly(A)+ RNA (2.5 jig) isolated from EIAV-infected FDD cells was fractionated on 1.4% agarose-formaldehyde denaturing gels and transferred to nitrocellulose membranes. The membrane was probed with one of three 32P-labeled synthetic oligonucleotides designed to be complementary to regions of the EIAV leader sequence or amino-terminal portions of the gag coding region. These probes were designed to be specific for the three putative splice donors in this region (see Fig. 2A Nuclease S1 protection assays. Total cellular RNA isolated from EIAV-infected or uninfected FDD cells was annealed to one of four different end-labeled probes (see Fig. 3 ), and the resulting complex was subjected to Si nuclease digestion to identify the splice sites of EIAV-specific mRNAs. Probe 1 (P1) was generated by subcloning a 308-bp TaqI-PvuII EIAV proviral DNA restriction fragment encompassing the three putative splice donor sequences near the amino terminus of the gag coding region into AccI-SmaI-digested M13mpl8 and then digesting it with Nar. The resulting probe contained a 294-bp NarI-PvuII EIAV-specific sequence (nt 326 to 620) followed by a 250-bp sequence derived from the SmaI to NarI restriction sites of M13mpi8. This probe was 3' end labeled with [L-32P] 585 -bp (SmaI-MscI) restriction fragment. These blunt-end DNAs were subcloned into SmaI-digested pSP65, generating pSP720 and pSP585, respectively, or into StuIdigested pSV2Acat, generating pSV720 and pSV585, respectively (Fig. 5A) . The resulting recombinant plasmids were screened for proper orientation by using appropriate restriction enzymes.
The EIAV LTR CAT plasmid, pLTRcat, used in transactivation assays has been previously described (7, 25) . The pSV2cat plasmid (11) , which contains the CAT gene under the control of the SV40 immediate-early promoter, was used as a positive control in CAT assay transfections. Transfection plasmids were purified by two rounds of cesium chloride density centrifugation as previously described (10) .
Plasmid DNA transfection and CAT assays. CsCl density gradient-purified DNA (11 ,ug) was used to transfect 60-mm petri dishes of FDD cells by the calcium phosphate coprecipitation method (10) . pLTRcat (5 ,ug) and pSV3-gal (1 ,ug) were cotransfected with pSV720, pSV585, or pSV2Acat (5 p,g). pSV3-gal plasmid (Promega Biotec) was added to each transfection to control for transfection efficiency. Cell lysates were prepared 48 h posttransfection as previously described (10) , and the P-galactosidase activities of the cell lysates from each transfection were measured according to the supplier's recommendations (Promega Corp.). pSV2cat (5 ,ug) was used as a positive control DNA for CAT activity and was cotransfected with pSV2Acat (5 ,g) and pSVP-gal ( ). The translation products were either directly analyzed on 20% low-molecular-weight polypeptide gels (Hoefer Scientific Instruments) or first subjected to radioimmunoprecipitation with the indicated antisera. Autoradiographic image enhancement was achieved by the use of Autofluor (National Diagnostics) according to the manufacturer's recommendations. The dried gels were exposed to Kodak XAR film at -70°C overnight.
Antiserum preparation and radioimmunoprecipitation assays. Synthetic peptides corresponding to portions of ORFs S1 and S2 were linked to keyhole limpet hemacyanin and injected into New Zealand White rabbits in Freund's complete adjuvant. The rabbits were boosted with the same antigen in Freund's incomplete adjuvant after 3 weeks to produce hyperimmune sera, which were harvested 2 weeks after the rabbits were boosted. The immunoglobulin G (IgG) fraction was partially purified from the sera by ammonium sulfate precipitation and DEAE-Sephadex column chromatography as previously described (5) . The appropriate antiserum was reacted with radiolabeled in vitro translation products for radioimmunoprecipitation as previously described (2). The precipitated proteins were analyzed on discontinuous sodium dodecyl sulfate (SDS)-polyacrylamide gels as described above.
Automated protein sequencing. The EIAV ORF S1 protein was synthesized in wheat germ extracts programmed with pSP720 RNA in the presence of [3H]arginine, as described above. The pSP720 transcript encodes both S1 and S2, which are difficult to completely resolve on SDS gels. Because of the similarity in the gel mobilities of the S1 and S2 proteins, the S1 protein was immunoprecipitated from the translation mixture prior to gel electrophoresis. The ORF S2 protein was synthesized in the presence of [3H]glycine from pSP585 RNA, which lacks sequences required for S1 expression. The S1 and S2 proteins were fractionated on 15% discontinuous gels (14) , which were placed directly into Autoflour for 30 min. The dried gels were exposed to Kodak XAR film and placed at -70°C overnight. With the autoradiograph as a template, the appropriate protein band was cut from the dried gel and rehydrated in a minimal volume of water. The gel slice was crushed, and the labeled proteins were eluted in 2 to 3 ml of Tris (Fig.1B) , were produced from a spliced RNA, which utilized a splice donor at nt 459 (sdl) and a splice acceptor at nt 5135 (sal). These cDNA clones correspond to an RNA that contains a majority of ORF S1, all of ORF S2, and the env gene (Fig. 1C) . The splicing event removed four codons from the 5' end of ORF S1 as it was originally defined (26) isolated from EIAV-infected FDD cells probed with each of the three 32P-labeled splice donor probes demonstrate that the 3.5-kb mRNA species can be detected only by the SD-1 probe (Fig. 2B, lane 1) , which suggests that sdl is the only splice donor utilized in this cell type to generate the singly spliced envelope message. The 8.2-kb genomic RNA hybridizes nearly equally well to each probe, suggesting consistency in the techniques employed and efficient labeling of the probes. The extremely low abundance of multiply spliced transcripts in this cell type (25) made it difficult to determine the potential usage of these alternative spliced donors in the generation of this class of RNAs. In an attempt to detect hybridization of the various probes to low-molecular-weight transcripts, the autoradiograph shown in Fig. 2 has been intentionally overexposed. This did not result in the detection of any clear signal corresponding to EIAV-specific transcripts of the 1.5-kb size class but rather resulted in the appearance of a diffuse nonspecific smear in this size range. In order to more clearly define the role of these three putative splice donors, we used the more-sensitive technique of nuclease Si protection. Nuclease Si protection analysis of spliced EIAV mRNAs. The utilization of the various near-consensus splice donor and acceptor sites (17, 23) identified within the EIAV genomic RNA by nucleotide sequence analysis was examined by nuclease Si protection assays of total cellular RNA isolated from EIAV-infected FDD cells. 32P-labeled restriction fragments of EIAV proviral DNA were used as probes in these assays (Fig. 3) .
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Analysis of the splice donors at the 5' end of the genome was accomplished by using a 5'-end-labeled 308-bp TaqIPvuII proviral restriction fragment (nt 309 to 620) with an M13 vector tag sequence at its 3' end (Fig. 3B, P1 ). When convenient, the probes were constructed with extraneous vector sequences to allow for distinction between input probe and probe annealed to full-length genomic RNA digestion (Fig. 4A, lane 1) . These fragments correspond to probe annealed to full-length EIAV genomic RNA and spliced RNA utilizing sdl, respectively. No protected fragments corresponding to sd2 and sd3 were detected, suggesting that these sequences are not utilized as splice donor sites in EIAV-infected FDD cells. This result is in agreement with that of the Northern blot experiment employing the differential splice donor oligonucleotide probes described above. That is, in FDD cells, apparently only the first splice donor in the leader region is utilized to generate singly or multiply spliced mRNAs.
The splice acceptor sites in the pol-env intergenic region were mapped with a 3'-end-labeled 450-bp NcoI-BamHI EIAV restriction fragment (nt 4889 to 5337) with 161 bp of M13mpl9 sequence tagged to its 5' end (Fig. 3B, P2 ). This probe was designed to investigate the utilization of the two near-consensus splice acceptor sites located near the 5' ends of ORF S1, sal (nt 5135), and sa2 (nt 5183). We have already shown by cDNA cloning and nucleotide sequence analysis of cDNA clones pSR-1 and pSR-2 that sal is functional. Probe P2 will allow us to determine whether the second splice acceptor is utilized and what the relative distribution of spliced transcripts employing either acceptor is. Protection of P2 from Si nuclease digestion by hybridization to fulllength genomic DNA is expected to protect a 450-nt portion of the input probe, while hybridization to spliced mRNAs utilizing sal or sa2 would be expected to yield protected fragments of 206 and 157 nt, respectively (Fig. 3B, P2) .
The experimental results clearly demonstrate protected fragments representative of all three classes of mRNAs, that is, unspliced genomic and spliced RNAs employing either sal or sa2 (Fig. 4B, lane 1) . Although equivalent amounts of total cellular RNA were used in each experiment, differences in the autoradiograph signals of the protected fragments for different probes may vary depending on the efficiency of probe labeling and hybridization and on autoradiograph exposure time. However, within a given experiment, it is possible to draw quantitative conclusions about the relative abundance of transcripts employing the individual splice sites. The intensity of the probe fragment protected by mRNAs utilizing sal is much greater than it is with mRNAs employing sa2, suggesting that mRNAs spliced at sa2 represent a minor population in EIAV-infected FDD cells. Furthermore, the sal-protected probe fragment is considerably more intense than that protected by the full-length genomic RNA, which is in agreement with our previously reported result that the 3.5-kb mRNA species is the predominant viral RNA in EIAV-infected FDD cells (25) .
The third probe (Fig. 3B, P3 ) was designed to determine the role of potential splice donor sites within the pol-env intergenic region in the formation of multiply spliced mRNA transcripts. This probe was generated from a 617-bp 5'-endlabeled PvuII-HindHII EIAV proviral restriction fragment (nt 5162 to 5775). There are four near-consensus splice donors localized from the 3' end of ORF S1 to the 3' end of ORF S2 at nt 5276, 5298, 5306, and 5435 (Fig. 3A) . RNA species utilizing these donor sites would be expected to yield protected fragments of 114, 136, 144, and 273 nt, respectively. In fact, only the 144-nt protected probe fragment could be detected (Fig. 4C, lane 1) , suggesting that only the splice donor sequence localized to nt 5306 is utilized in FDD cells for the generation of multiply spliced mRNAs. This finding was somewhat surprising, in that multiply spliced ORF Sl-ORF S3 RNAs isolated from canine fibroblasts were shown to involve splicing from the donor site immediately downstream of ORF S1 at nt 5276 (30) . We were unable to detect a protected fragment 114 nt in length corresponding to a similar splicing event in FDD cells. It should be noted that the design of probe P3 from the PvuII site prevents detection of multiply spliced mRNA species, which are produced by splicing events involving sa2, since the labeled portion of the probe would be unable to hybridize to such messages and would therefore be digested by nuclease S1. Therefore, we cannot conclude that the other splice donor sequences within this region are not utilized to generate multiply spliced messages. Further study is required to determine the role of sa2 in both singly and multiply spliced RNAs.
The final S1 protection probe (P4) was designed to investigate the potential usage of a splice acceptor site at the 5' end of ORF S3 (sa3, nt 7234), which may result in the provision of an AUG translational initiation codon for the protein product encoded by this ORF. Probe P4 corresponds to a 3'-end-labeled-385 bp DraI-ScaI proviral restriction fragment (nt 7026 to 7412). This probe is expected to yield a 385-nt fragment when annealed to full-length genomic RNA and a 178-nt fragment when hybridized to spliced mRNA utilizing sa3. The Si mapping results show the presence of the 178-nt protected fragment, indicative of usage of sa3.
The nuclease S1 protection experiments described herein (Fig. 1C) (25) . Cotransfection of the pSV720 expression plasmid with pLTRcat clearly results in trans activation of the EIAV LTR, as evidenced by an increase in CAT enzyme activity of more than 60-fold compared with that resulting from transfection with the pLTRcat plasmid alone (Fig. SB) . Cotrans The pSP720 and pSP585 plasmid DNAs were employed as transcription templates to produce synthetic capped RNAs, which were translated in wheat germ extracts in the presence of [3H]leucine. In vitro translation of pSP720 RNA resulted in the synthesis of three major polypeptide products with relative molecular sizes of 15, 8.5, and 7 kDa (Fig. 6A, lanes  1 and 8) . These products correspond closely to the predicted sizes of MscI-truncated gp9O envelope protein, the EIAV Tat protein, and the putative ORF S2 protein, respectively. The pSP585 RNA supported translation of only two of these products, the 15-and 7-kDa polypeptides (Fig. 6A, lane 5) . The 15-kDa product from both pSP585 and pSP720 RNAprogrammed translation reactions was specifically immunoprecipitated with a monoclonal antibody directed against an epitope of the gp9O envelope protein mapping to a region approximately 50 amino acids from its amino terminus (3) (Fig. 6A, lanes 2 and 6) . The 8.5-kDa band specific for pSP720 RNA translation could be immunoprecipitated by a rabbit polyclonal antiserum produced against a synthetic peptide corresponding to a predicted immunoreactive domain of the EIAV Tat protein (Fig. 6A, lane 3) . The 7-kDa protein common to both pSP720 and pSP585 RNA translation reactions was immunoprecipitated by a combination of low-titer rabbit polyclonal antisera produced against four different overlapping synthetic peptides that span the entire ORF S2 amino acid sequence (Fig. 6A, lanes 4 and 7) . This combination of ORF S2 antisera cross-reacted with the EIAV Tat protein product (Fig. 6A, lane 4) . However, a high-titer ORF S2 antiserum obtained more recently demonstrated no cross-reactivity with EIAV Tat (Fig. 6A, lane 9) . This ORF S2 antiserum also specifically precipitates two minor products with mobilities of 5.5 and 4 kDa, which are presumed to be either S2-related peptides produced by translational initiation at the internal AUG codons of S2 or degradation products of S2. These data indicate that a single cDNA species corresponding to the 3.5-kb singly spliced mRNA of EIAV is capable of directing the synthesis of the EIAV Tat, the S2 protein, and the envelope protein in vitro. Furthermore, since no EIAV Tat protein product is detected upon translation of pSP585 RNA, sequences located between the StuI site in the R region and the SmaI site in the leader, which include the predicted CUG initiation codon of EIAV Tat, are required for in vitro expression of the EIAV Tat protein.
Humoral immune response to the ORF S2 protein in EIAVinfected horses. The predicted protein product of ORF S2 bears no significant sequence homology to any known lentiviral protein, and to date, no protein product has been shown to be encoded by ORF S2 in vivo. In an effort to establish whether an ORF S2-encoded polypeptide is produced during productive EIAV infection, we have examined sera from EIAV-infected horses for the presence of antibodies to the putative ORF S2 gene product. We have accomplished this goal by examining the abilities of these sera to recognize the in vitro translated product in an immunoprecipitation reaction and by testing the reactivity of a panel of horse sera to ORF S2-specific synthetic peptides in ELISAs.
The ORF S2 polypeptide and a portion of the gp9O envelope protein were synthesized in wheat germ extract from a synthetic RNA similar to that produced by the pSP585 plasmid described above. The transcription template in this experiment differed from pSP585 in that it included sequences from the MscI (nt 5655) to the first HindIII (nt 5775) restriction endonuclease digestion sites in the env gene. This additional envelope sequence results in the synthesis of a truncated gp9O protein with an apparent molecular size of approximately 20 kDa on SDS-polyacrylamide gels. The 35S-labeled in vitro translation products were immunoprecipitated with sera obtained from an EIAV-infected horse followed by SDS-polyacrylamide gel electrophoresis (PAGE) analysis. Analysis of the in vitro translation products shows the synthesis of the 20-kDa truncated envelope protein and the 7-kDa ORF S2 polypeptide (Fig. 6B, lane 1) . These labeled products were immunoprecipitated with 4 or 20 ,ug of partially purified IgG obtained from the serum of an EIAV-infected horse (Fig. 6B, lanes 2 and 3, respectively) . As one would anticipate, the truncated gp9O envelope protein reacts strongly with the EIAV-infected horse IgG fraction, particularly at the higher concentration (Fig. 6B, in wheat germ extracts programmed with pSP585 RNA was purified from an SDS-polyacrylamide gel and subjected to amino-terminal sequencing. Amino acid fractions in 100% acetonitrile were directly placed in Liquiscint liquid scintillation solvent and assayed for radioactivity. The S1 protein was prepared in a similar manner by translation of pSP720 in vitro transcripts in the presence of [3H]arginine.
The amino acid sequences of the predicted S2 and S1 polypeptides are aligned beneath the peaks of radioactivity assayed from the automated Sequenator.
we determined the presumptive translation initiation sites of the in vitro-synthesized ORF Si and ORF S2 proteins by amino-terminal sequencing of radiolabeled polypeptides. The radioactive amino acid of choice for sequencing of the ORF S2 protein was [3H]glycine, since the first methionine codon in ORF S2 is followed immediately by a glycine codon and since three of the first seven codons correspond to glycine residues. The ORF Si protein was labeled with [3H]arginine, since translational initiation at the proposed CUG codon (8, 30) would place two contiguous arginine residues near the amino terminus.
The ORF S2 product was synthesized from pSP585 RNA, and approximately 7 x 104 cpm of gel-purified protein was subjected to amino-terminal sequence analysis. The sequencer fraction corresponding to the first amino acid residue registered in excess of 7 x 103 cpm, while further peaks of radioactivity were observed for amino acid residues 4 and 6 (Fig. 7A) . The anticipated amino acid sequence of the S2 polypeptide initiating at the first methionine codon in this ORF is M G L F G K G. Assuming that the amino peptidase activity of the wheat germ extract has cleaved the initiator methionine residue from this protein, the peaks of radioactivity occur precisely as expected, that is, in fractions 1, 4, and 6. Additional peaks of radioactivity were noted in fractions 16, 17, and 20, which are also predicted sites of glycine residues in the ORF S2 protein. These data confirm that the in vitro-synthesized polypeptide assigned to be encoded by ORF S2 on the basis of its ability to specifically react with ORF S2-specific peptide antisera is indeed the ORF S2 gene product and that its synthesis in vitro is apparently initiated at the first methionine residue in this ORF.
The sequence of the ORF Si protein, EIAV Tat, was of particular interest, since it has been suggested that this protein may initiate translation at a CUG codon. Of the two CUG codons located within the leader region, the one more downstream (nt 373) lies in the most favorable sequence context for translation initiation (12 sponding to the third and fourth residues of the polypeptide (Fig. 7B) . The positions of these peaks are consistent with translational initiation at the previously proposed CUG codon, presuming amino peptidase processing of the initiator methionine residue. On the basis of these findings, we propose that the amino terminus of the in vitro-synthesized EIAV Tat protein is blocked by an unknown functional group and that limited translation time followed by heat treatment allowed us to capture a fraction of the newly synthesized Tat genes. It appears highly unlikely that any envelope RNA which does not also contain ORF S2 will be detected, since there are only 26 nt separating the presumptive AUG initiation codons of S2 and the gpi35 envelope gene product, and no reasonable splice acceptor sequences lie in this region. Indeed, we were unable to detect in FDD cells any functional splice acceptor sites that map to this region by Si nuclease protection analysis. Therefore, singly spliced 3.5-kb RNAs involving sa2 may be bicistronic in nature, encoding the S2 and gpi35 proteins in a manner similar to that by which the HIV-1 Vpu and gpi60 proteins are encoded (28) .
The possibility remains that either of the identified splice acceptor sites (sal and sa2) could be involved in the production of multiply spliced transcripts. Of the four putative splice donor sequences in the pol-env intergenic region, only one, located between the ORF S2 and the env AUG initiation codons, was detected in these studies to be functional in FDD cells. The splice acceptor site (sa3) near the 5' end of ORF S3 is also functional in these cells, suggesting the possibility that the ORF S2 AUG is spliced to ORF S3, thus providing a translational initiation for S3 expression. However, direct splicing of the splice donor within ORF S2 (nt 5306) to the ORF S3 acceptor site (nt 7235) would not result in proper alignment of the S2 AUG with the S3 coding frame. Only two additional codons, neither of which is an AUG, would be placed in frame with S3. The third exon of the triply spliced ORF Si-ORF S3 RNA identified in EIAVinfected canine cells consists of a short stretch of sequence from the env gene which appears to provide a translational initiation codon to ORF S3 (30) . It remains possible that an exon within the env coding region provides a stretch of amino acid-coding potential allowing for proper alignment of S3 with the S2 AUG.
Translational potential of the major 3.5-kb transcript. The major 3.5-kb EIAV transcript of FDD cells is shown here to be tricistronic in vitro, encoding the protein products of the ORF Si, ORF S2, and env genes in the wheat germ cell-free translation system. Amino-terminal sequence analysis of in vitro-synthesized EIAV Tat is consistent with initiation at a CUG codon (nt 373), which lies in an otherwise favorable sequence context for translational initiation, AAC CUG G, in which underlined nucleotides match the consensus sequence for translation initiation (12) . We have shown EIAV Tat synthesis from cDNA sequences corresponding to the 5' end of the 3.5-kb transcript in vivo, as evidenced by a 60-fold increase in CAT expression directed by the EIAV LTR. The relatively low levels of trans activation observed for EIAV compared with those reported for HIV may reflect differences in the amount of trans-activator protein produced as a result of initiation at the suboptimal CUG codon.
Serum samples from EIAV-infected horses are immunoreactive with both in vitro-synthesized S2 protein and synthetic peptides corresponding to portions of S2. Characterization of viral envelope variants propagated from horse macrophage cultures infected with horse-virulent EIAV has shown that although a number of mutations arise throughout the gp9O-coding sequence and in the major coding exon for the S3 protein, no mutations occur in ORF S2 (1) . Taken together, these data strongly indicate a role for the ORF S2 gene product during EIAV infection, although no function for this protein has yet been defined.
Although a number of singly spliced HIV-1 transcripts contain multiple ORFs (28, 29, 31) , only the vpu-env (28) transcripts are known to act as multicistronic transcripts in vivo. The HIV-1 transcript encoding the 72-amino-acid form of the Tat protein, Tat-1, is structurally similar to the major EIAV 3.5-kb transcript described here in that it contains the tat-i, vpu, and env genes in positions nearly identical to those of the EIAV tat, ORF S2, and env genes (28) . This HIV transcript has been shown to be monocistronic in vivo, producing only the Tat-1 protein, presumably because of the relatively strong translation initiation codon of the Tat protein (GAA AUG G). Similarly, infrequent translation initiation of EIAV Tat from an inefficient non-AUG codon and of the S2 protein from an AUG codon in a relatively weak sequence context (UAU AUG G) may allow significant leaky ribosomal scanning (13) to the highly favorable gp135 AUG (AAC AUG G) of the major 3.5-kb transcript (sdl-sal).
During the preparation of this paper, a report which seems to suggest translational initiation of EIAV Tat in transfected canine fibroblasts from an AUC codon (nt 388) upon deletion of sequences including the CUG (nt 373) initiation codon identified here was published (22) . This result is somewhat surprising, since this AUC codon (AGG AUC C) lies in a less favorable context for translation initiation than does the CUG codon (AAC CUG G). It is possible that deletion of the more favorable CUG could allow synthesis at the next most favorable codon, the AUC. Clearly, future studies involving site-specific mutagenesis of each codon and its surrounding sequence are required to determine which is the actual translation initiator in EIAV-infected cells.
